Consensus $253.07M. Cuts FY25 adjusted EBITDA view to $13.5M-$14.5M from $27M-$29M. The company said, “For the full year 2025, the Company’s guidance reflects revenue and adjusted EBITDA as a stand-alone telehealth company following the WorkSimpli divestiture and reflecting a $1.1 million adjustment in 2025 related to the November 5, 2025 press release.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFMD:
- LifeMD reports Q3 EPS (10c), consensus 5c
- LifeMD sees Q4 revenue $45M-$46M, consensus $63.07M
- LifeMD options imply 13.7% move in share price post-earnings
- LifeMD announces new, lower cash-pay price for GLP-1 medications
- Novo launches introductory self-pay offer for Wegovy, Ozempic for $199 per month